
Rimini Street和ServiceNow與Apsen Farmacêutica合作,實現企業級工作流程自動化的下一代願景
Apsen將業務需求置於技術之上,採用靈活的模組化企業資源規劃(ERP)方法,實現持續創新並掌控IT投資。達成這一目標的第一步是擺脫對供應商和系統的依賴,首先從其SAP ERP平台投資開始。
Apsen Farmacêutica資訊長Renan Santos表示:「三年前制定的策略核心是引進一個有能力變革IT的團隊,採用『自製、購買或融合』的構想,以協調的方式連接公司的所有系統。在這個過程中,SAP的問題出現了。隨著SAP宣布2027年後將不再支援SAP ECC 6,我們面臨一個選擇——承擔移轉到S/4HANA的成本、干擾和風險,或者重新構想現有的系統,使其成為一個創新平台。就在那時,我們與Rimini Street合作,實施ServiceNow的ERP現代化解決方案。」
Rimini Street執行長Seth Ravin表示:「我們非常高興能與ServiceNow和Apsen Farmacêutica合作,交付這項下一代技術——它可以輕鬆地部署在其現有的SAP ECC 6 ERP和其他目前的企業軟體平台之上,無需進行高成本、高風險且不必要的升級或移轉。我們很驕傲能協助Aspen透過節省系統升級和移轉的成本,為其創新投資實現自籌資金。Apsen在簡化流程、降低營運成本和提高營運效率方面看到了立竿見影的成效。」
ServiceNow核心業務工作流程、產品和解決方案行銷副總裁Peter Russo表示:「ServiceNow很高興能與Rimini Street合作,將我們的共同解決方案和下一代ERP現代化願景帶給Apsen Farmacêutica——Apsen在專案啟動幾周後就從該解決方案中實現了價值。相較創新投資,ERP和其他企業軟體的升級和移轉通常無法提供可觀的投資報酬率。Apsen是一個絕佳的範例,展示了ServiceNow和Rimini Street如何共同為全球企業帶來價值、節省成本,並加快實現創新、現代化和自主AI的進程。」
Rimini Street:與ServiceNow合作實現「無干擾轉型」(Transformation without Disruption™)
Rimini Street和ServiceNow合作,向市場推出了一項新解決方案,透過將ServiceNow平台與Rimini Street針對SAP、Oracle、Infor、Microsoft ERP和其他孤立企業軟體的成熟企業軟體支援相結合,實現「無干擾轉型」,無需進行昂貴的升級、移轉或重新搭建平台。
借助這一新解決方案,Rimini Street能夠:
取代軟體供應商對底層ERP和企業軟體的支援,將總支援成本降低高達90%,同時保證將軟體和版本的生命週期至少延長15年,無需進行升級或移轉
透過在現有ERP、軟體即服務(SaaS)和其他軟體之上及之間部署ServiceNow層,釋放資金和資源以投資于加快創新
提供強大的企業AI和整合的企業「單一視窗」視圖,提供可操作的營運洞察並強化競爭優勢
連接孤立的系統和資料
實施智慧工作流程和任務自動化,有助於提高生產力並減少勞動力需求
為使用者提供新的現代化螢幕以及行動功能、互動和體驗(使用者體驗)
敏捷性、自動化和成本撙節——無需升級或移轉
Santos表示:「儘管公司進行了大量投資,但身為一名技術專業人員,我以個人和企業員工的身分經歷了兩種截然不同的體驗,這令人非常沮喪。融合這兩個領域是我和我的團隊共同的目標。我們一直在尋找一種敏捷的解決方案,它能夠快速帶來價值,並避免任何大型軟體移轉專案固有的成本、複雜性和風險,而Rimini Street與ServiceNow的創新解決方案是我們實現轉型願景的最快且最可靠的途徑。」
在Rimini Street為Apsen Farmacêutica的關鍵任務SAP ECC系統提供全面支援的情況下,Santos及其團隊輕鬆地將SAP任務和客製化功能轉換為ServiceNow智慧工作流程,連接了所有必要的現有系統和團隊。Apsen Farmacêutica遵循其可組合性和靈活性策略,選擇了低程式碼/無程式碼工具並整合了AI,為工作流程帶來內建式智慧,進而實現即時的營運分析。
Apsen Farmacêutica與Rimini Street和ServiceNow合作的成果包括:
之前需要大量人工介入的流程中,70%如今已實現自動化
將新流程的開發週期從數月縮短至數周
減少對高度專業化團隊的依賴,推動整個企業實現自主流程開發以滿足業務需求
在提高速度和效率的同時降低營運成本
該公司看到了Santos願景的成果和益處,即擺脫傳統的由供應商驅動的指令,將控制權和權力重新交回企業手中,這對企業的文化產生了重大影響。Santos表示:「我們設立了一支強大的內部團隊,現在這個團隊有能力以策略性的方式重新思考流程、供應商和架構。最初的下一代願景和試點專案已成為整個公司的典範。」
Apsen Farmacêutica計畫擴充該解決方案,實現物流、品質和財務等其他關鍵流程的自動化。Santos補充道,Rimini Street對SAP ECC 6等關鍵任務系統以及ServiceNow解決方案的深入瞭解為該企業帶來了新的現實。
Santos還表示:「我們的重點仍然是保持目前系統的穩定和安全,同時建立一個能夠實現持續和敏捷創新的架構。這一策略性合作夥伴關係將協助我們在安全、可擴充和持續提升效率的基礎上不斷成長。」
在 此處 進一步瞭解Apsen Farmacêutica與Rimini Street和ServiceNow合作實現「無干擾轉型」的歷程。
關於Rimini Street, Inc.
「羅素2000指數」(Russell 2000®)公司Rimini Street, Inc. (Nasdaq: RMNI)是端對端企業軟體支援和創新解決方案的全球供應商,以及Oracle、SAP和VMware軟體的領先支援服務協力廠商。該公司提供全面的統一解決方案組合,用於運行、管理、支援、自訂、設定、連接、保護、監控和最佳化企業應用程式、資料庫和技術軟體。該公司已與《財星》全球100大企業、《財星》500大企業、中型企業、公共部門和政府機構簽署了數千份合約,這些機構選擇Rimini Street為其值得信賴、經驗證的關鍵任務企業軟體解決方案供應商,實現更好的營運成果,節省數十億美元的開銷,用於為AI和其他創新投資提供資金支援。
ServiceNow、ServiceNow標誌、Now、Now Platform及其他ServiceNow標誌均為ServiceNow, Inc.在美國和/或其他國家的商標和/或注冊商標。
如欲瞭解更多資訊,請造訪 www.riministreet.com ,並在 X 、 Facebook 、 Instagram 和 LinkedIn 上與Rimini Street聯絡。
前瞻性陳述
本新聞稿中的某些陳述並非歷史事實,而是《1995年私人證券訴訟改革法案》安全港條款所定義的前瞻性陳述。前瞻性陳述通常含有以下字詞:「預期」、「假設」、「相信」、「繼續」、「可以」、「目前」、「估計」、「預計」、「預報」、「未來」、「打算」、「也許」、「或許」、「前景」、「計畫」 、」可能」、「目標」、「潛力」、「預測」、「推測」、「似乎」、「尋求」、「應該」、「將」、「會」或其他類似字詞、片語或表述。這些前瞻性陳述包括但不限於我們對未來事件、未來機會、全球擴張及其他成長計畫和我們對此類計畫的投資之預期的陳述。這些陳述根據不同的假設以及管理層目前的預期,並非是對實際業績的預測,也非歷史事實。這些陳述受制於有關Rimini Street業務的一系列風險和不確定性,實際結果可能會大相逕庭。這些風險和不確定性包括但不限於:未決訴訟或任何新訴訟的不利發展和相關抗辯成本,包括未決上訴動議的處置和任何新索賠;為遵守法院就Rimini II訴訟事宜下達的任何禁令而產生的任何支出,以及對未來期間收入和與這些工作相關的成本的影響;Rimini Street經營所在的商業環境的變化,包括任何總體經濟衰退趨勢、地緣政治緊張加劇和外匯匯率變化的影響,以及影響我們經營所在產業和我們客戶經營所在產業的一般金融、經濟、監管和政治狀況的影響;企業軟體管理與支援格局的演進,以及我們對市場進行教育以吸引和留住客戶並進一步滲透客戶群的能力;軟體支援服務行業的激烈競爭以及我們關於公司定價模式的意圖;客戶對我們擴大的產品和服務組合以及我們預期推出的產品和服務的採用情況;我們對新產品、合作夥伴關係和聯盟計畫的預期,包括但不限於我們與ServiceNow的合作關係;我們的營收成長能力、準確預測營收的能力,以及根據目前的營收預期和產品擴大而管理成本的結果;上一財政年度和本財政年度裁員的預期影響以及相關的重整成本;我們對總目標市場的估計,以及相對於使用其他供應商而言客戶節省成本的預期;我們銷售週期的時間變化;與保留率相關的風險,包括我們準確預測保留率的能力;我們管理團隊一名或多名成員的流失;我們吸引和留住更多合格人員的能力;我們的業務計畫、未來成長能力以及實現和維持獲利的能力;我們計畫終止為Oracle PeopleSoft產品提供服務;我們股價的波動性及相關證券交易要求的法規遵循;我們以有利條件進行股權或債務融資的需求和能力,以及我們從營運中獲得現金流以協助為我們的成長計畫增加投資提供資金的能力;與全球營運相關的風險;我們防止未經授權存取我們的資訊技術系統及其他網路安全威脅的能力;我們或我們的第三方供應商及服務供應商可能使用的生成式人工智慧(AI)技術相關的任何缺失;我們保護員工及客戶機密資訊以及遵守隱私權法規的能力;我們維持有效財務報告內部控制系統的能力;我們維持、保護及提升品牌和智慧財產權的能力;法律法規的變更,包括稅法的變更或我們採取的稅務立場的不利結果;關稅成本(包括鑑於美國政府實施的新關稅或提高的關稅,以及受影響國家採取報復性貿易措施的可能性,所涉及的關稅減免或降低關稅的能力);我們未能建立足夠的稅務儲備;我們實現淨營業損失利益的能力;環境、社會與治理議題對我們的聲譽或業務造成的任何負面影響,以及我們的業務因報告此類議題而面臨的額外成本或風險;我們與美國政府及國際政府保持良好合作關係及與政府實體簽署新合約的能力;我們的信用貸款對我們的業務及相關利率風險的持續還債義務以及財務和營運契約;我們的現金及現金等價物是否足以滿足我們的流動資金需求;根據我們的股票回購計畫進行回購(如有)的金額及時間,以及我們透過該計畫提升股東價值的能力;Rimini Street股權證券長期價值的不確定性;擾亂我們或我們客戶業務的災難性事件;以及在 Rimini Street於2025年5月1日遞交的Form 10-Q季度報告中「風險因素」標題下討論的風險因素,以及Rimini Street未來的Form 10-K年度報告、Form 10-Q季度報告、Form 8-K當期報告和Rimini Street遞交給美國證券交易委員會的其他文件中不時更新的風險因素。此外,前瞻性陳述提供了截至本通訊稿發表之日Rimini Street對未來事件和觀點的預期、計畫或預測。Rimini Street預計後續事件和事態發展將導致Rimini Street的評估發生變化。然而,儘管Rimini Street可能會在未來某個時間點選擇更新這些前瞻性陳述,但Rimini Street特別聲明,除法律規定之外,公司沒有任何這方面的義務。這些前瞻性陳述不應被視為代表Rimini Street在本通訊稿發表之日後任何日期的評估結果。
© 2025 Rimini Street, Inc。保留所有權利。「Rimini Street」是Rimini Street, Inc.在美國及其他國家的註冊商標,Rimini Street、Rimini Street標誌及其組合,以及其他以TM標示的標記均為Rimini Street, Inc.的商標。所有其他商標均為其各自擁有者的財產,除非另有說明,否則Rimini Street與任何此類商標持有人或本文提及的其他公司並無關聯、認可或聯繫。
免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Rivian Stock Slips as Morgan Stanley Slashes Price Target to $12
Aug 12 - Rivian (NASDAQ:RIVN) stock dipped about 2.5% Tuesday morning after Morgan Stanley trimmed its price target to $12 from $13 while keeping an Equal-weight rating. Traders reacted to Morgan Stanley's cautious tone on Rivian's upcoming R2 launch and heavy capital needs to compete in autonomy. Rivian trades near $11.69 with a market cap around $14.5 billion and sits down more than 10% year-to-date. Warning! GuruFocus has detected 5 Warning Signs with RIVN. Morgan Stanley said Rivian shows promise in AI-enabled autonomy but expressed reservations about the steering-wheel-equipped R2 and current EV demand headwinds. The bank also noted that Rivian's Volkswagen partnership may steady volatility but could cap upside. Other brokers downgraded pressure: UBS cut its target to $12, DA Davidson to $13, TD Cowen to $13, Piper Sandler to $14, and Stifel to $16, each pointing to margin pressure, tariff effects, or production downtime ahead of R2. Collectively, analysts weigh between the long term potential of Rivian and near term risks of execution. As it gets ready to launch the next batch of vehicles, investors will be eyeing R2 rollout information, margins forecast and cash management by the management. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Why Independent Bank (INDB) Stock Is Trading Up Today
What Happened? Shares of regional banking company Independent Bank (NASDAQ:INDB) jumped 3.8% in the afternoon session after a broad market rally fueled by renewed optimism for a Federal Reserve interest rate cut and a positive development in U.S.-China trade relations. The broader market surge, which particularly benefited the financial sector, is being fueled by two key factors. Firstly, a weaker-than-expected inflation report has boosted investor confidence that the Federal Reserve may cut interest rates, potentially as soon as next month. This prospect of monetary easing creates a favorable environment for economic growth. Secondly, the extension of a U.S.-China tariff truce has reduced concerns about trade disputes, further improving overall market sentiment. This combination of events has led to a "risk-on" atmosphere, encouraging investment in equities. The shares closed the day at $66.89, up 3.9% from previous close. Is now the time to buy Independent Bank? Access our full analysis report here, it's free. What Is The Market Telling Us Independent Bank's shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 11 days ago when the stock dropped 3.2% on the news that a surprisingly weak July jobs report and the announcement of sweeping new tariffs fueled fears of an economic slowdown and an impending interest rate cut. The U.S. economy added just 73,000 jobs in July, the weakest gain in over two years, while the unemployment rate rose to 4.2%. This dismal data significantly increased market expectations for a Federal Reserve interest rate cut, with traders now pricing in an 80% probability of a cut in September. Lower interest rates typically harm bank profitability by compressing their net interest margins—the difference between what they earn on loans and pay on deposits. Compounding these worries, the announcement of new tariffs on imports from 92 countries has sparked fears of a global trade war, which could further dampen economic growth and disrupt supply chains, creating a challenging environment for the banking industry. Independent Bank is up 5.9% since the beginning of the year, but at $66.90 per share, it is still trading 10.8% below its 52-week high of $74.97 from November 2024. Investors who bought $1,000 worth of Independent Bank's shares 5 years ago would now be looking at an investment worth $962.59. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Why Roivant Sciences Stock Bounced Back on Tuesday
Key Points A day after it published its latest set of quarterly earnings, an analyst bumped his price target higher. He also maintained his equivalent of a buy recommendation. 10 stocks we like better than Roivant Sciences › Monday's hangover turned into Tuesday's party for healthcare stock Roivant Sciences (NASDAQ: ROIV). On the back of a modest but meaningful analyst price target hike, investors bid the stock up by nearly 4% following a post-earnings slide the day before. With the Tuesday rise, Roivant handily beat the benchmark S&P 500 index, which bumped 1.1% higher. Boosting the biotech Tuesday's raiser was Leerink Partners prognosticator David Risinger. Well before market open, he added $1 to his Roivant price target for a new level of $18 per share. In doing so, he maintained his recommendation of outperform (read: buy) on the company's stock. According to reports, Risinger's adjustment is based on a change in his forecast for the biotech company's share count. The analyst based this on management's statements about its share repurchase program, which is expected to shave the tally for shares outstanding. As for Roivant's operations, the pundit waxed bullish on the eventual outcome of the company's phase 3 clinical trial of brepocitinib in the treatment of dermatomyositis, a rare inflammatory disease that can affect the muscles and the skin. He's anticipating a readout of the trial to be published in the second half of this year. A first quarter to forget Risinger's continued bullishness on Roivant was a morale-booster for the market, which had traded out of the company's shares after Monday's fiscal first quarter of 2026 earnings release. The company reported significantly lower revenue compared to the same period of 2025, and it flipped to a net loss on the bottom line. Should you buy stock in Roivant Sciences right now? Before you buy stock in Roivant Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Roivant Sciences wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy. Why Roivant Sciences Stock Bounced Back on Tuesday was originally published by The Motley Fool Sign in to access your portfolio